Table 2 |
|||
|
Summary of differentially expressed genes in the lymph node cells of different groups of Lewis rats tested ex vivo and in vitroa |
|||
|
DEGs, n (%) |
|||
|
Characteristics |
Upregulation |
Downregulation |
Total |
|
|
|||
|
Ex vivo |
|||
|
Inc/Nv |
322 (100%) |
0 (0%) |
322 |
|
Pk/Nv |
31 (53.4%) |
27 (46.6%) |
58 |
|
Rec/Nv |
28 (80%) |
7 (20%) |
35 |
|
In vitro |
|||
|
Preclinical arthritis rats |
41 (67.2%) |
20 (32.8%) |
61 |
|
Preclinical Bhsp65-tolerized rats |
579 (98%) |
12 (2%) |
591 |
|
|
|||
|
aDEG: differentially expressed gene. "Ex vivo" group shows DEGs in lymph node cells (LNCs) at incubation (Inc), peak (Pk) or recovery (Rec) phase compared to naïve (Nv) state; "in vitro" group shows DEGs induced by mycobacterial heat shock protein 65 (Bhsp65) compared to baseline control (LNCs cultured in medium alone). In Bhsp65-tolerized group, only 76 (12.86%) of the 579 DEGs were related to immune activity (innate immunity, cell-mediated immunity and humoral immunity). The major groups comprised genes relating to cellular proliferation 127 (21.5%) and metabolism 137 (23.2%). |
|||
|
Yu et al. Arthritis Research & Therapy 2011 13:R143 doi:10.1186/ar3457 |
|||
